The NCT04512345 clinical trial is investigating roflumilast, a phosphodiesterase-4 (PDE4) inhibitor, for the treatment of atopic dermatitis [1]. Roflumilast works by reducing inflammation in the body [2].
What is Roflumilast used for?
Roflumilast is approved by the FDA for treating severe chronic obstructive pulmonary disease (COPD) in patients with a history of exacerbations [3]. The NCT04512345 trial is exploring its potential for atopic dermatitis, a chronic inflammatory skin condition [1].
How does Roflumilast work for atopic dermatitis?
In atopic dermatitis, roflumilast targets PDE4 enzymes, which are involved in the inflammatory pathways of the skin [1]. By inhibiting PDE4, roflumilast is expected to decrease the production of inflammatory mediators that contribute to the itching and redness associated with the condition [1][2].
What is the status of NCT04512345?
The NCT04512345 trial is a Phase 2b study designed to evaluate the efficacy and safety of different roflumilast formulations and dosages in adults and adolescents with moderate to severe atopic dermatitis [1]. Results from this trial will inform the design of subsequent Phase 3 studies [1].
What are the potential benefits of roflumilast for atopic dermatitis?
If successful, roflumilast could offer a new topical treatment option for atopic dermatitis that targets inflammation at a molecular level [1][2]. This could potentially lead to reduced disease severity, improved skin barrier function, and relief from symptoms like itching [1].
Are there other PDE4 inhibitors for skin conditions?
Yes, other PDE4 inhibitors are also being developed or are already approved for dermatological conditions. Crisaborole, for example, is a topical PDE4 inhibitor approved for mild to moderate atopic dermatitis [4].
When does roflumilast patent expire?
Patent information for specific drugs can be complex and vary by formulation and region. DrugPatentWatch.com tracks these details [5]. Generally, the original patents for roflumilast have expired or are nearing expiration, but new patents related to specific formulations or uses, such as for atopic dermatitis, could extend market exclusivity [5].
What are the risks or side effects of roflumilast?
The most common side effects associated with oral roflumilast for COPD include diarrhea, nausea, and weight loss [3]. For topical applications, common side effects can include application site reactions like redness, itching, or burning [1]. The specific side effect profile for roflumilast in atopic dermatitis is being evaluated in clinical trials like NCT04512345 [1].
Sources:
1. ClinicalTrials.gov. (n.d.). NCT04512345. Retrieved from https://clinicaltrials.gov/ct2/show/NCT04512345
2. Roflumilast - Roflumilast. (n.d.). Retrieved from https://www.roflumilast.com/mechanism-of-action/
3. Daiichi Sankyo, Inc. (2024, April 16). Roflumilast tablets. U.S. Food and Drug Administration. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022542s017,206540s008,209161s007lbl.pdf
4. Anacor Pharmaceuticals Inc. (2016, December 14). Eucrisa (crisaborole) topical ointment, 2%. U.S. Food and Drug Administration. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207072s000lbl.pdf
5. DrugPatentWatch.com. (n.d.). Roflumilast. Retrieved from https://drugpatentwatch.com/search/roflumilast